Market capitalization | $39.16m |
Enterprise Value | $104.20m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.60 |
P/S ratio (TTM) P/S ratio | 0.23 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 33.11% |
Revenue (TTM) Revenue | $173.82m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a FibroGen, Inc. forecast:
3 Analysts have issued a FibroGen, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 174 174 |
33%
33%
|
|
Gross Profit | 133 133 |
19%
19%
|
|
EBITDA | -141 -141 |
55%
55%
|
EBIT (Operating Income) EBIT | -147 -147 |
55%
55%
|
Net Profit | -168 -168 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Thane Wettig |
Employees | 486 |
Founded | 1993 |
Website | www.fibrogen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.